Cannabis extract drug may help patients with rheumatoid arthritis

NewsGuard 100/100 Score
GW Pharmaceuticals plc announces positive preliminary results in a Phase II clinical trial in patients with pain caused by Rheumatoid Arthritis.

The multi centre double blind, randomised, parallel group study in 58 patients assessed the efficacy, safety and tolerability of Sativex®, a whole plant medicinal cannabis extract, compared with placebo for the treatment of pain caused by Rheumatoid Arthritis. Study medication was administered by means of a spray into the mouth as an evening dose only and measures were assessed the following day.

In the Phase II trial, statistically significant improvements were seen in a range of outcome measures including morning pain at rest (p<0.05), quality of sleep (p<0.05), disease activity score (p<0.01) and Short Form McGill Pain Questionnaire – pain at present (p<0.05). Analysis of morning pain on movement approached statistical significance in favour of Sativex.

Overall the number of adverse events experienced was similar between the treatment groups. The safety profile was consistent to that shown in previous Sativex studies with adverse events being generally mild or moderate in intensity.

Dr Philip Robson, Director of GW’s Cannabinoid Research Institute, said, “These results are particularly exciting because this is the first ever controlled clinical trial of a cannabis-based medicine in the treatment of arthritis. To date, GW’s research has concentrated on multiple sclerosis and neuropathic pain and it is therefore very encouraging to see these positive effects of Sativex on pain and other symptoms of rheumatoid arthritis. Future research in rheumatoid arthritis will examine the optimal cannabinoid ratios in this indication prior to selecting the product candidate to enter into a pivotal Phase III trials programme.

Dr Robson added, “This exploratory trial provides further strong support to our belief that cannabis-based medicines may offer therapeutic potential across a range of medical conditions.”


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers unveil unique autoantibody profiles in rheumatoid arthritis patients